Anixa Biosciences, Inc. ANIX

ANIX Company Overview

Anixa Biosciences, Inc. is a biotechnology company focused on developing cancer therapeutics and vaccines, with a primary emphasis on immuno-oncology and women’s health-related cancer treatments. The company operates within the broader biotechnology and life sciences industries and concentrates on early-stage therapeutic development through academic and research collaborations. Its principal programs have centered on a breast cancer vaccine initiative and CAR-T cell therapy technologies targeting ovarian cancer. Public filings and company disclosures identify research and development activities as the company’s primary operational focus, with revenue historically derived from licensing arrangements and legacy intellectual property activities rather than commercialized drug sales.

The company evolved from its earlier identity as ITUS Corporation, which itself originated from a technology and intellectual property licensing business before shifting strategic focus toward biotechnology and oncology research. Following this transition, the company adopted the Anixa Biosciences name to reflect its life sciences orientation. Anixa’s strategic positioning is tied to collaborations with leading research institutions, including partnerships associated with Cleveland Clinic and Moffitt Cancer Center, which provide access to specialized oncology research capabilities and clinical development pathways.